2bind is a provider for biophysical analytical services operating in a fee-for-service business model. Our broad portfolio of biophysical assays for hit identification, validation and characterisation allows our customers to accelerate and streamline key research processes in their early drug discovery programs.
Anteris medical supports the pharmaceutical, biotech and medical device industries globally by managing the development of combination products, medical devices or in vitro diagnostics. Our broad competencies cover compliance, regulatory affairs combined with innovative, resource-efficient solutions for compliant development and technical documentation as well as marketing and sales expertise.
Metrion Biosciences is an ion channel focused CRO offering integrated drug discovery services, CiPA compliant cardiac safety profiling, phenotypic assays, translational assays and custom screening services on a fee-for-service or collaboration basis. Metrion’s know-how and breadth of services adds value to drug discovery programs by developing and de-risking ion channel modulators as they progress towards nomination for clinical development.
Nanion is a leading provider of automated patch clamp systems with throughput capabilities ranging from a single cell up to fully automated high throughput screening instruments recording from 384 cells simultaneously. Our portfolio contains furthermore analysis devices for membrane pump and transporter recordings (SURFE²R), bilayer recordings (Orbit), and cell monitoring/contractility measurements (CardioExcyte 96).
Assay.Works will attend the upcoming 2023 BIO International Convention June 5-8, 2023, in Boston, Massachusetts, for partnering opportunities. If you are interesting in meeting Dr. Ralf Schwandner, our CEO, stop by at the German Pavilion, booth #1435, or get in touch using the partnering tool.
We are excited to announce the acquisition of Assay.Works by Partex N.V., a Digital Pharma platform contributing to the biopharma value chain, from Data to Drugs. Partex is registered in Amsterdam, The Netherlands, and headquartered in Eschborn, Germany.
Joining forces with Partex will allow us to build a stable, long-term perspective by expanding our market reach, leveraging synergies, and continuing to invest in our capabilities.
Business will continue as usual. Assay.Works GmbH will operate as a separate legal entity and our management and scientific team will continue working with you in their current roles.
Transient receptor potential (TRP) channels are important targets for discovering novel drugs in a variety of indications, including neuropathic pain or cancer. Together with our partners AcCELLerate and Nanion, we established the pharmacology of recombinant cell lines expressing TRPA1, TRPM8, TRPV1, TRPV3, or TRPV4, in a fluorescent Ca2+-flux assay as well as automated patch-clamp. The cell lines are available as assay-ready frozen cells and can be used directly after thawing for substance screening or profiling of lead candidates.
Assay.Works builds on the legacy of the HTS Center of a leading biopharmaceutical company where we provided assay, screening, and quantitative biology services for drug discovery programs across therapeutic areas with high medical need. During our 16-year tenure, we developed and implemented more than 250 screens spanning all major drug target classes, and generated over 100,000,000 data sets.
Founder and CEO
Biologist and seasoned Lead Discovery specialist with 18 years of experience in the biopharmaceutical industry. Prior to founding Assay.Works, he served as head of Amgen‘s HTS center of excellence at Regensburg, Germany (Amgen Research GmbH).
Founder and COO
Biochemist with 16 years of industry experience in Lead Discovery. Most recently, he was head of Research Operations at Amgen Research GmbH, where he managed Sample Management, cell-based Lead Profiling, Cell Production, Informatics, and EH&S.
Assay.Works GmbH
Am BioPark 11
93053 Regensburg
Germany
T +49 941 2000 1240
F +49 941 2000 1241
please enable javascript to view
www.assay.works